Combination of anti-her2 antibodies for the treatment of disease
By combining anti-HER2 bispecific antibodies with taxanes or irinotecan, the lack of effective treatments for HER2-positive gastric cancer that has progressed or recurred after first-line therapy has been addressed, resulting in a significant extension of progression-free survival and overall survival for patients.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI JMT BIO TECHNOLOGY CO LTD
- Filing Date
- 2025-09-07
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of effective drugs in the current technology for patients with HER2-positive gastric cancer who have progressed or relapsed after first-line treatment, especially for adenocarcinoma of the gastroesophageal junction, and systemic drug therapy is particularly important for patients with advanced gastric cancer in China.
We offer combination therapies for anti-HER2 bispecific antibodies with taxanes or irinotecan, including anticancer agents such as paclitaxel, docetaxel, or irinotecan, for the treatment of HER2-positive gastric cancer. These are administered intravenously, with optimized administration sequence and dosage to improve treatment efficacy.
It significantly prolonged progression-free survival and overall survival in patients with HER2-positive gastric cancer, with median progression-free survival increased to at least 7.1-7.2 months and median overall survival increased to at least 19.6-26.5 months.
Smart Images
Figure SMS_1 
Figure SMS_2